DEF: Inspire Medical Systems Reports Strong 2025, Proposes Board Declassification

Inspire Medical Systems, Inc. announces robust 2025 financial and operational growth, including $912 million in revenue and over 125,000 patients treated, alongside proposals for board declassification and an equity plan amendment.

Summary

• Generated $912 million in revenue for the full year 2025, a 14% increase over full year 2024.
• Surpassed 125,000 patients treated with Inspire therapy.
• Achieved adjusted net income of $72.1 million and adjusted net income per diluted share of $2.42 for full year 2025.
• Reported a net income of $145.4 million for 2025, a significant increase from $53.5 million in 2024.
• Delivered strong gross and adjusted operating margins of 85.4% and 7.3%, respectively, for full year 2025.
• Increased adjusted EBITDA by 26% to $200.6 million for full year 2025 from $157.8 million for full year 2024.
• Operating cash flow for the full year was $117.0 million.
• Launched the Inspire V neurostimulation system in the U.S., reinforcing commitment to innovation.
• Exceeded 385 peer-reviewed publications related to Inspire therapy.
• The Board proposes to declassify its structure, phasing out staggered terms for annual director elections beginning with the 2029 annual meeting of stockholders.
• Seeking stockholder approval for an amendment and restatement of the 2018 Incentive Award Plan to increase authorized shares to 9,903,857 and remove the evergreen feature.
• Repurchased $175.0 million of Inspire common stock in 2025 and ended the year with over $400 million in cash, cash equivalents, and investments.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance report with clear strategic initiatives. The company demonstrates robust financial growth, significant patient adoption, and proactive governance improvements. While 'underwater' options present a challenge for talent retention, the proposed equity plan aims to address this, and the overall financial health and strategic direction are positive.

Positives

• Strong financial performance in 2025, with 14% revenue growth to $912 million and a 26% increase in adjusted EBITDA to $200.6 million.
• Significant progress on profitability, with net income rising to $145.4 million and adjusted net income at $72.1 million.
• High gross margin of 85.4% and adjusted operating margin of 7.3% reflect disciplined execution.
• Reached a milestone of over 125,000 patients treated with Inspire therapy, indicating strong market adoption.
• Successful launch of the Inspire V neurostimulation system in the U.S., demonstrating continued product innovation.
• Proactive corporate governance improvements, including a proposal to declassify the Board for annual director elections starting 2029, aligning with stockholder feedback.
• Broad-based employee equity program, with over 80% of employees participating in 2025, fostering alignment with long-term stockholder outcomes.
• Shareholder-friendly capital allocation demonstrated by the repurchase of $175.0 million of common stock in 2025.
• Maintained a strong liquidity position with over $400 million in cash, cash equivalents, and investments at year-end 2025.

Negatives

• Nearly 90% of outstanding stock options held by employees were 'underwater' as of February 23, 2026, with a weighted average exercise price of $173.31, limiting their intrinsic value for retention and motivation.
• Stock price has experienced increased volatility due to challenging conditions, industry-wide sector headwinds, and shifts in the medical device reimbursement and coding landscape, as well as perceived uncertainty in the reimbursement process.
• The need to request an additional 2.6 million shares for the equity plan (representing 9.0% of common shares outstanding) indicates a depleted equity pool and potential reliance on increased cash compensation if not approved, impacting capital allocation.

Risks

• Stock price volatility due to challenging conditions, industry-wide sector headwinds, and shifts in the reimbursement and coding landscape, including perceived uncertainty in the medical device reimbursement process.
• Inability to attract and retain talented employees if the proposed amendment to the 2018 Incentive Award Plan is not approved, potentially impacting business objectives.
• Increased reliance on cash compensation if the equity plan is not approved, which would reduce the ability to allocate capital towards strategic initiatives.
• Legal-related expenses and potential liabilities from a civil investigative demand from the Department of Justice and ongoing patent infringement suits with Nyxoah S.A.
• Information security and technology risks, including cybersecurity threats, which are overseen by the Audit Committee.
• Risks related to product quality, safety, and supply matters, including the effectiveness of quality management systems, significant product complaints, recalls, and FDA regulatory inspections and warning letters.

Future Outlook

The company expects to continue its growth trajectory, supported by strategic leadership enhancements and ongoing innovation. The proposed equity plan amendment is intended to support talent attraction and retention for future success, with the requested shares expected to last approximately one year. The Board will continue to regularly evaluate governance practices and consider stockholder perspectives.

Management Comments

• Our Board and management team led us through another year of substantial financial and operational performance.
• In 2025, we delivered strong results as adoption of Inspire therapy continued to grow.
• We have positioned our management team to enable our next phase of growth.
• Equity compensation is a cornerstone of how we attract, motivate and retain our most important asset – our people.
• We are confident our Board and management team bring the right combination of skills, experience, and commitment to continue driving financial and operational excellence and creating long term value for all stakeholders.

Industry Context

StockSavvy.ai notes that Inspire Medical Systems operates in the growing medical technology sector, specifically addressing Obstructive Sleep Apnea (OSA) with its neurostimulation technology. The company's strong revenue growth and patient adoption indicate a successful market penetration strategy, especially with the launch of the Inspire V system. The focus on profitability and disciplined execution aligns with broader industry trends where investors increasingly seek sustainable growth alongside innovation. The challenges with stock price volatility and 'underwater' options, despite strong operational performance, highlight the sensitivity of the medical device sector to reimbursement landscapes and broader market headwinds, a common theme for companies reliant on complex regulatory and payment structures.

Comparison to Industry Standards

• The company's 2025 revenue growth of 14% and adjusted EBITDA growth of 26% demonstrate strong performance within the medical technology sector, particularly for a company approaching the $1 billion revenue milestone.
• The 3-year average equity burn rate of 3.04% (or 2.62% adjusted) and projected overhang of 27.05% (21.67% excluding underwater options) are metrics that should be benchmarked against peer medical device companies to assess dilution and compensation efficiency. While the filing mentions a peer group for compensation (e.g., Atricure, Inari Medical, Pulmonx Corporation), it does not provide direct comparative financial performance metrics against these specific companies in terms of revenue growth or profitability.
• The company's gross margin of 85.4% is indicative of a high-value medical device product, often seen in specialized therapeutic areas, and compares favorably to many broader healthcare equipment manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• Civil investigative demand from the Department of Justice.
• Patent infringement suit filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc.
• Patent infringement suit brought against us by Nyxoah.

Related Party Transactions

• In 2025, the Company paid Dudley Capital Partners, LLC (an entity controlled by CEO Timothy P. Herbert) an aggregate of $190,892 under a Cost Sharing Agreement for a corporate suite at the XCEL Energy Center. The agreement, entered into on December 21, 2023, provides the Company with 50% usage rights for 50% of the yearly suite fee ($240,000, increasing 5% annually after the first year).

Stakeholder Impact

• Shareholders: Potential for increased long-term value through continued growth, improved governance (board declassification), and alignment of executive incentives. Dilution from the proposed equity plan increase is a consideration, though mitigated by share repurchases and removal of evergreen feature.
• Employees: Equity compensation program aims to attract, motivate, and retain talent, despite challenges with 'underwater' options. Management changes are intended to support future growth.
• Patients: Continued commitment to enhancing lives through sleep innovation, with over 125,000 patients treated and the launch of the Inspire V system.
• Customers (Clinical Community): Expanding engagement with Inspire therapy, evidenced by over 385 peer-reviewed publications.
• Regulatory Authorities: Ongoing compliance with legal and regulatory requirements, including FDA approvals and addressing legal proceedings.

Next Steps

• Hold 2026 Annual Meeting of Stockholders on April 30, 2026, to vote on director elections, auditor ratification, executive compensation, frequency of say-on-pay votes, board declassification, and equity plan amendment.
• Publish 2025 Sustainability Report in the second quarter of 2026.
• Continue to regularly evaluate governance practices and consider stockholder perspectives.
• Further align long-term incentive compensation practices, including adjusting target equity award opportunities and eligibility.
• If Proposal No. 5 is approved, file Certificate of Amendment with the Delaware Secretary of State promptly after the Annual Meeting to phase out classified Board structure.
• If Proposal No. 6 is approved, the amended and restated 2018 Incentive Award Plan will become effective.
• Next advisory say-on-pay vote expected at 2027 annual meeting of stockholders.
• Annual election of all directors to begin with the 2029 annual meeting of stockholders.

Key Dates

Recommendation

The filing indicates strong financial and operational performance in 2025, with significant revenue growth, improved profitability, and robust cash flow. The company's continued innovation, patient adoption, and proactive steps in corporate governance (board declassification) are positive indicators. While the 'underwater' options are a concern for employee retention, the proposed equity plan amendment aims to address this, and the company's overall trajectory suggests continued market leadership in the OSA treatment space. The share repurchase program also demonstrates a commitment to shareholder value. These factors collectively point to a favorable outlook for long-term investors.

Keywords

Inspire Medical Systems, OSA, Obstructive Sleep Apnea, Neurostimulation, Medical Technology, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Stock Options, RSUs, PSUs, Board Declassification, Share Repurchase, Financial Performance, Revenue Growth, Profitability, Talent Retention, Risk Management, FDA Approved, Inspire V